Literature DB >> 28236341

EDNRB mutations cause Waardenburg syndrome type II in the heterozygous state.

Sarah Issa1,2,3, Nadege Bondurand1,2,3, Emmanuelle Faubert4, Sylvain Poisson5, Laure Lecerf1,2, Patrick Nitschke6, Naima Deggouj7, Natalie Loundon8, Laurence Jonard5,9, Albert David10, Yves Sznajer11, Patricia Blanchet12, Sandrine Marlin3,9, Veronique Pingault1,3,4,5,13.   

Abstract

Waardenburg syndrome (WS) is a genetic disorder characterized by sensorineural hearing loss and pigmentation anomalies. The clinical definition of four WS types is based on additional features due to defects in structures mostly arising from the neural crest, with type I and type II being the most frequent. While type I is tightly associated to PAX3 mutations, WS type II (WS2) remains partly enigmatic with mutations in known genes (MITF, SOX10) accounting for only 30% of the cases. We performed exome sequencing in a WS2 index case and identified a heterozygous missense variation in EDNRB. Interestingly, homozygous (and very rare heterozygous) EDNRB mutations are already described in type IV WS (i.e., in association with Hirschsprung disease [HD]) and heterozygous mutations in isolated HD. Screening of a WS2 cohort led to the identification of an overall of six heterozygous EDNRB variations. Clinical phenotypes, pedigrees and molecular segregation investigations unraveled a dominant mode of inheritance with incomplete penetrance. In parallel, cellular and functional studies showed that each of the mutations impairs the subcellular localization of the receptor or induces a defective downstream signaling pathway. Based on our results, we now estimate EDNRB mutations to be responsible for 5%-6% of WS2.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  G protein-coupled receptor; Waardenburg syndrome; endothelin; neurocristopathy

Mesh:

Substances:

Year:  2017        PMID: 28236341     DOI: 10.1002/humu.23206

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

Review 1.  Genetic insights, disease mechanisms, and biological therapeutics for Waardenburg syndrome.

Authors:  Sida Huang; Jian Song; Chufeng He; Xinzhang Cai; Kai Yuan; Lingyun Mei; Yong Feng
Journal:  Gene Ther       Date:  2021-02-25       Impact factor: 4.184

2.  A reporter mouse model for in vivo tracing and in vitro molecular studies of melanocytic lineage cells and their diseases.

Authors:  Melissa Crawford; Valerie Leclerc; Lina Dagnino
Journal:  Biol Open       Date:  2017-08-15       Impact factor: 2.422

3.  A Novel Spontaneous Mutation of the SOX10 Gene Associated with Waardenburg Syndrome Type II.

Authors:  Sen Chen; Yuan Jin; Le Xie; Wen Xie; Kai Xu; Yue Qiu; Xue Bai; Hui-Min Zhang; Xiao-Zhou Liu; Xiao-Hui Wang; Wei-Jia Kong; Yu Sun
Journal:  Neural Plast       Date:  2020-08-28       Impact factor: 3.599

4.  Two Genomic Loci Control Three Eye Colors in the Domestic Pigeon (Columba livia).

Authors:  Emily T Maclary; Bridget Phillips; Ryan Wauer; Elena F Boer; Rebecca Bruders; Tyler Gilvarry; Carson Holt; Mark Yandell; Michael D Shapiro
Journal:  Mol Biol Evol       Date:  2021-12-09       Impact factor: 16.240

5.  Whole-genome sequencing reveals the artificial selection and local environmental adaptability of pigeons (Columba livia).

Authors:  Haobin Hou; Xiaoliang Wang; Weixing Ding; Changfeng Xiao; Xia Cai; Wenwei Lv; Yingying Tu; Weimin Zhao; Junfeng Yao; Changsuo Yang
Journal:  Evol Appl       Date:  2021-08-05       Impact factor: 4.929

6.  Prenatal detection of chromosomal abnormalities and copy number variants in fetuses with congenital gastrointestinal obstruction.

Authors:  Xinyue Meng; Lili Jiang
Journal:  BMC Pregnancy Childbirth       Date:  2022-01-19       Impact factor: 3.007

7.  High Genetic Heterogeneity in Chinese Patients With Waardenburg Syndrome Revealed by Next-Generation Sequencing.

Authors:  Sen Zhang; Hongen Xu; Yongan Tian; Danhua Liu; Xinyue Hou; Beiping Zeng; Bei Chen; Huanfei Liu; Ruijun Li; Xiaohua Li; Bin Zuo; Ryan Tang; Wenxue Tang
Journal:  Front Genet       Date:  2021-06-04       Impact factor: 4.599

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.